PRECLUDE PERICARDIAL MEMBRANE

K012098 · W. L. Gore & Associates, Inc. · DXZ · Sep 20, 2001 · Cardiovascular

Device Facts

Record IDK012098
Device NamePRECLUDE PERICARDIAL MEMBRANE
ApplicantW. L. Gore & Associates, Inc.
Product CodeDXZ · Cardiovascular
Decision DateSep 20, 2001
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 870.3470
Device ClassClass 2
AttributesTherapeutic

Intended Use

For reconstruction and repair of the pericardium

Device Story

PRECLUDE Pericardial Membrane is a biocompatible, expanded polytetrafluoroethylene (ePTFE) sheet with nominal pore size < 1 µm. Used as a physical barrier to limit tissue attachment to the membrane and underlying surfaces, including temporary mechanical circulatory assist devices. Device is implanted by surgeons during cardiac procedures. Material is inert and biocompatible; acts as a protective membrane to prevent adhesions between the pericardium and surrounding tissues. No changes to device technology or materials were made in this submission; modification is limited to labeling (Warnings and Precautions) regarding use with mechanical circulatory assist devices.

Clinical Evidence

No new clinical or bench testing was performed for this submission. Evidence relies on previously documented animal studies and clinical literature demonstrating that ePTFE material with < 1 µm pore size effectively limits tissue-to-membrane attachment.

Technological Characteristics

Biocompatible, expanded polytetrafluoroethylene (ePTFE) sheet; nominal pore size < 1 µm; various width and length dimensions; inert material.

Indications for Use

Indicated for reconstruction and repair of the pericardium.

Regulatory Classification

Identification

An intracardiac patch or pledget made of polypropylene, polyethylene terephthalate, or polytetrafluoroethylene is a fabric device placed in the heart that is used to repair septal defects, for patch grafting, to repair tissue, and to buttress sutures.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ SEP 2 0 2001 ## Attachment 4 510 (k) Premarket Notification PRECLUDE® Pericardial Membrane ### Premarket Notification 510(k) Summary - A. Submitted By: W.L. Gore & Associates, Inc. P.O. Box 500 Flaqstaff, AZ 86002-0500 Date Prepared: September 17, 2001 Contact : R. Larry Pratt Phone: 928-779-2771 - PRECLUDE® Pericardial Membrane Device Name: B. - c. Applicant Device Description: Biocompatible, expanded polytetrafluoroethylene (ePTFE). The ePTFE material has a nominal pore size of < 1 µm. The device is in sheet configuration with a variety of width and length dimensions. - D. Predicate Device: The currently marketed PRECLUDE® Pericardial Membrane is cited as the predicate device which has been found to be substantially equivalent through the premarket notification process. - E . Applicant Device Labeling: Like the predicate device, the applicant device is indicated for the reconstruction or repair of the pericardium. The indication statement for the predicate device is not changed as a result of this submission's clearance. The WARNINGS section and the PRECAUTIONS section of the Instructions For Use are modified to provide special care {1}------------------------------------------------ information for when the device is employed as a protective membrane and physical barrier to limit tissue attachment to the membrane and thus to the surface of a temporary mechanical circulatory assist device. #### Technological Characteristics: F. This premarket notification represents a modification to the labeling only. The technological characteristics of the predicate device are not changed. The applicant device the predicate doving the same inert, biocompatible ePTFE material as the predicate device, consequently bench testing was not performed. Reports of data from animal studies and from clinical experiences documented in the literature demonstrate that ePTFE material with a nominal pore size of < 1 µm limits tissue to membrane attachment and thus attachment between surfaces that it covers and surrounding tissue. - Safety and Effectiveness Conclusions: G. This submission represents only a modification to the WARNINGS section and the PRECAUTIONS section of the Instructions For Use for the currently marketed predicate device. Therefore, the similarities between the applicant and predicate device are numerous. These equivalencies combine to justify a substantially equivalent determination. The only difference from the predicate device to the applicant device is that the WARNINGS section and the PRECAUTIONS section of the Instructions For Use for the applicant device provides special care information for when the device is employed as a protective membrane and physical barrier to limit tissue attachment to the membrane and thus to the surface of a mechanical circulatory assist device. This difference does not adversely affect the safety, integrity, therapeutic effect or functional characteristics of the applicant device when compared to the predicate device. No new types of safety and effectiveness questions are raised by the applicant device when compared to the predicate device. GORE-TEX®, GORE® and PRECLUDE® are trademarks of W.L. Gore & Associates {2}------------------------------------------------ Image /page/2/Picture/1 description: The image is a circular logo for the Department of Health & Human Services - USA. The logo features the department's name in a circular arrangement around a central emblem. The emblem consists of a stylized design of three human profiles facing to the right, stacked on top of each other. Public Health Service SEP 2 0 2001 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Mr. R. Larry Pratt Regulatory Affairs W. L. Gore and Associates, Inc. Medical Products Division 3750 West Kiltie Lane Flagstaff. AZ 86002 Re: K012098 Trade Name: PRECLUDE® Pericardial Membrane Regulation Number: 21 CFR 870.3470 Regulation Name: Intracardiac Patch or Pledget Made of Polypropylene, Polyethylene Terephthalate, or Polytetrafluoroethylene Regulatory Class: Class II (two) Product Code: DXZ Dated: September 17, 2001 Received: September 18, 2001 Dear Mr. Pratt: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {3}------------------------------------------------ # Page 2 - Mr. R. Larry Pratt Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, James D. Dillard III Director Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ 510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________ Device Name: PRECLUDE Pericardial Membrane Indications For Use: For reconstruction and repair of the pericardium (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) ze Division of Cardiovascular & Respiratory Devices 510(k) Number K011098 Prescription Use (Per 21 CFR 801.109) OR Over-The-Counter Use (Optional Format 1-2-96)
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%